Reuters Events | Pharma

Thought leadership and innovation for the Pharmaceutical Industry

GlaxoSmithKline (GSK) inked a deal yesterday with the Indian generics manufacturer Dr.

GlaxoSmithKline (GSK) inked a deal yesterday with the Indian generics manufacturer Dr. Reddys Laboratories giving it access to over 100 future generic drugs and a gateway to Asias emerging pharmaceutical markets. The therapeutic areas covered under the agreement include diabetes, cardiovascular, pain management, gastroenterology and oncology. Dr Reddys Laboratories is one of Indias largest generic drug manufacturers. Like many of its competitors, Dr. Reddys Laboratories also have active development programs for new biotechnology drugs and biosimilar products.

UK-based, GSK joins a growing number of pharmaceutical companies including Pfizer, Merck and others that have entered into deals with major generic drug manufacturersor purchased smaller generics companiesto gain access to generics pipelines and an ability to compete in emerging non-branded pharmaceutical markets. Impending US healthcare reform and downward pricing pressures (resulting from increased global competition) have forced drug makers to reevaluate the role that generic drugs will likely play in future pharmaceutical revenue streams.

While generic drug makers have outstanding manufacturing capabilities, they generally lack the marketing, sales and distribution channels necessary to penetrate foreign markets and quickly ramp up drug sales. I suspect that the number of deals between pharmaceutical companies and generic manufacturers will continue to increase as many of the patents for multibillion, blockbuster drugs continue to expire in the next few years.

Please visit www.biojobblog.com and www.biocrowd.com to participate in the discussion about healthcare reform and drug pricing